EUVIMEDEUVIMED entdecken
Crossref

Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets

Fidele Y Musangile, Ibu Matsuzaki, Ryuta Iwamoto, Kanako Sagan, Mizuki Nishikawa, Yurina Mikasa, Yuichi Takahashi, Fumiyoshi Kojima, Isao Hara, Shin-Ichi Murata

Modern Pathology · 2023-05 · 36 (5) · 100120

DOI: 10.1016/j.modpat.2023.100120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-05. Verfasst von Fidele Y Musangile und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flat urothelial lesions are controversial diagnostic and prognostic urologic entities whose importance relies mainly on their ability to progress to muscle-invasive tumors via urothelial carcinoma in situ (CIS). However, the carcinogenetic progression of preneoplastic flat urothelial lesions is not well established. Moreover, predictive biomarkers and therapeutic targets of the highly recurrent and aggressive urothelial CIS lesion are lacking. Using a targeted next-generation sequencing (NGS) panel of 17 genes directly involved in bladder cancer pathogenesis, we investigated alterations of genes and pathways with clinical and carcinogenic implications on 119 samples of flat urothelium, including normal urothelium (n = 7), reactive atypia (n = 10), atypia of unknown significance ( n = 34), dysplasia ( n = 23), and CIS (n = 45). The majority of the flat lesions were tumor-associated but grossly/microscopically or temporally separated from the main tumor. Mutations were compared across flat lesions and concerning the concomitant urothelial tumor. Associations between genomic mutations and recurrence after intravesical bacillus Calmette-Guerin treatment were estimated with Cox regression analysis. TERT promoter mutations were highly prevalent in intraurothelial lesions but not in the normal or reactive urothelium, suggesting that it is a critical driver mutation in urothelial tumorigenesis. We found that synchronous atypia of unknown significance-dysplasia-CIS lesions without concomitant papillary urothelial carcinomas had a similar genomic profile that differed from atypia of unknown significance-dysplasia lesions associated with papillary urothelial carcinomas, which harbored significantly more FGFR3, ARID1A, and PIK3CA mutations. KRAS G12C and ERBB2 S310F/Y mutations were exclusively detected in CIS and were associated with recurrence after bacillus Calmette-Guerin treatment (P = .0006 and P = .01, respectively). This targeted NGS study revealed critical mutations involved in the carcinogenetic progression of flat lesions with putative pathobiological pathways. Importantly, KRAS G12C and ERBB2 S310F/Y mutations were identified as potential prognostic and therapeutic biomarkers for urothelial carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in SituHumansUrotheliumBCG VaccineProto-Oncogene Proteins p21(ras)BiomarkersHyperplasiaHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

CISNext-generation sequencingatypical urotheliumdysplasiaflat urothelial lesionurothelial carcinoma

Substanzen

BCG VaccineProto-Oncogene Proteins p21(ras)Biomarkers

Autor:innen und Institutionen

  • Department of Human Pathology, Wakayama Medical University, Wakayama, Japan.
  • Department of Urology, Wakayama Medical University, Wakayama, Japan.
  • Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. Electronic address: smurata@wakayama-med.ac.jp.

Zitieren

APA

Musangile, F. Y., Matsuzaki, I., Iwamoto, R., Sagan, K., Nishikawa, M., Mikasa, Y., Takahashi, Y., Kojima, F., Hara, I., & Murata, S. I. (2023). Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets. Modern Pathology, 36(5), 100120. https://doi.org/10.1016/j.modpat.2023.100120

Vancouver

Musangile FY, Matsuzaki I, Iwamoto R, Sagan K, Nishikawa M, Mikasa Y, et al. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets. Modern Pathology. 2023;36(5):100120. doi:10.1016/j.modpat.2023.100120

BibTeX
@article{Musangile2023,
  author = {Musangile, Fidele Y and Matsuzaki, Ibu and Iwamoto, Ryuta and Sagan, Kanako and Nishikawa, Mizuki and Mikasa, Yurina and Takahashi, Yuichi and Kojima, Fumiyoshi and Hara, Isao and Murata, Shin-Ichi},
  title = {Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {5},
  pages = {100120},
  doi = {10.1016/j.modpat.2023.100120}
}
Kostenlos starten →